Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen

Purpose: Prediction of impaired tamoxifen (TAM) to endoxifen metabolism may be relevant to improve breast cancer treatment, e.g., via TAM dose increase. The polymorphic cytochrome P450 2D6 (CYP2D6) strongly determines an individual’s capacity for endoxifen formation, however, CYP2D6 phenotype assign...

Full description

Bibliographic Details
Main Authors: Werner Schroth, Stefan Winter, Thomas Mürdter, Elke Schaeffeler, Diana Eccles, Bryony Eccles, Balram Chowbay, Chiea C. Khor, Arafat Tfayli, Nathalie K. Zgheib, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-08-01
Series:Frontiers in Pharmacology
Subjects:
endoxifen
CYP2D6 polymorphism
metabolizer phenotype
tamoxifen
breast cancer
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00582/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00582/full

Similar Items